Enasidenib, aslo known as AG-221 and CC-90007, is a potent and selective IDH2 inhibitor with potential anticancer activity (IDH2 = Isocitrate dehydrogenase 2). The mutations of IDH2 present in certain cancer cells result in a new ability of the enzyme to catalyze the NAPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG). The production of 2HG is believed to contribute to the formation and progression of cancer . The inhibition of mutant IDH2 and its neoactivity is therefore a potential therapeutic treatment for cancer.
Cianchetta, Giovanni; DeLaBarre, Byron; Popovici-Muller, Janeta; Salituro, Francesco G.; Saunders, Jeffrey O.; Travins, Jeremy; Yan, Shunqi; Guo, Tao; Zhang, Li. Aryltriazinediamine compounds as IDH2 inhibitors and their preparation and use in the treatment of cancer. WO 2013102431. (Assignee Agios Pharmaceuticals, Inc., USA)
Chopra, Vivek Saroj Kumar; Dimartino, Jorge; Kenvin, Laurie A.; Knight, Robert Douglas; MacBeth, Kyle; Viswanadhan, Krishnan; Xu, Qiang; Agresta, Samuel V.. Combination therapy for treating hematological malignancies. WO 2017066611. (Assignee Celgene Corporation, USA; Agios Pharmaceuticals, Inc.)
Agresta, Samuel V.; Gu, Chong-Hui; Schenkein, David; Yang, Hua; Guo, Liting; Tang, Zhen; Wang, Jianming; Zhang, Yanfeng; Zhou, Yan. Therapeutically active compounds and their methods of use. WO 2015017821. (Assignee Agios Pharmaceuticals, Inc., USA)
Agresta, Samuel V. Antitumor compounds and their methods of use. US 20160089374. (Assignee Agios Pharmaceuticals, Inc., USA)
Xia, Xiaoyang; Zhang, Dawei. Preparation of heterocyclic compounds as IDH2 inhibitors. WO 2016177347. (Assignee Teligene Ltd., Peop. Rep. China)
Zhang, Shijie. Method for preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diol and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine. WO 2017024134. (Assignee Agios Pharmaceuticals, Inc., USA)
Agresta, Samuel V. Combination therapy for treating malignancies such as acute myeloid leukemia (AML) with an IDH2 mutation using and inhibitor of mutant IDH2 and AML induction and consolidation therapy. WO 2017066599. (Assignee Agios Pharmaceuticals, Inc., USA)
Kluge, Stefan. Preparation of therapeutically active compounds and their methods of use. Assignee Agios Pharmaceuticals, Inc., USA. WO 2016126798. 2016.
